Prevention of Ulcer Recurrence After Eradication of Helicobacter pylori: A Prospective Long-term Follow-up Study

RENEW. M. VAN DER HULST,* ERIK A. J. RAUWS,* BIRCOK KÖYCU,* JOSBERT J. KELLER,* MARCO J. BRUNO,* JAN G. P. TIJSSEN,† and GUIDO N. J. TYTGAT*

Departments of *Gastroenterology and Hepatology and †Clinical Epidemiology, Academic Medical Center, Amsterdam, The Netherlands

Background & Aims: Short-term follow-up studies show lower relapse rates of duodenal and gastric ulcers after successful Helicobacter pylori eradication. The aim of this study was to determine the long-term outcome of ulcer disease after successful H. pylori eradication.

Methods: We prospectively studied the long-term effect of H. pylori eradication on ulcer recurrence rates in patients after endoscopically proven healing of duodenal or gastric ulcers between 1984 and 1995. Patients using nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or maintenance antisecretory therapy were excluded. H. pylori infection was assessed by culture and histopathology of gastric biopsy specimens. After endoscopically proven ulcer healing and successful H. pylori eradication, 186 patients with ulcers underwent elective endoscopy every 3 months during the first year of follow-up and were advised to contact us at symptom recurrence. Thereafter, 96 patients were available for elective half-yearly endoscopies. The 89 patients who did not choose to undergo the repeated endoscopies were asked about symptom recurrence and to undergo elective endoscopy in 1995. Results: Successful H. pylori eradication was achieved in 141 patients with duodenal ulcers and 45 patients with gastric ulcers. None of the 141 H. pylori–eradicated patients with duodenal ulcers had an ulcer relapse after follow-up of 367 patient-years. Ulcer relapses were also absent in the 45 H. pylori–eradicated patients with gastric ulcers after 113 patient-years of follow-up. Conclusions: Excluding patients taking aspirin or NSAIDs, recurrence of duodenal or gastric ulcers is completely prevented after successful H. pylori eradication for up to 9.8 years.

The pathogenic role of Helicobacter pylori in chronic active gastritis and its association with duodenal ulcer disease in 95%–99% of patients are well established.1–3 Therefore, the 1994 National Institutes of Health Consensus Development Conference recommended eradication of H. pylori in all patients with documented peptic ulcer disease.4 Several studies of 1-year follow-up in patients with duodenal ulcers indicate that eradication of H. pylori dramatically reduces ulcer relapse rates.2–24 The few studies in patients with gastric ulcers had similar findings.2,25–29 Only a few studies have followed up on patients with duodenal ulcers for more than 1 year.30,31 All these studies report ulcer relapses (3%–22%) despite successful H. pylori eradication. Factors clarifying the variance in study results include the varying end points: absence of documented initial ulcer disease and ulcer healing; unknown H. pylori status at the time of ulcer relapse or at the conclusion of the study;14,17,18,25 and the assessment of cure of the infection by H. pylori clearance instead of H. pylori eradication, a difference leading to high rates of H. pylori recrudescence and ulcer relapse rates.5,9,12,26 Moreover, the use of nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or maintenance histamine2-receptor antagonist (H2RA) may influence reported ulcer relapse rates. To obtain more detailed information on the clinical outcome in patients with peptic ulcers after prolonged follow-up, we conducted a prospective study with scheduled follow-up endoscopies every 3 months for the first year, after initial ulcer healing (endoscopy) and H. pylori eradication (culture and histology) was confirmed. Thereafter, elective half-yearly endoscopies were performed in half of the patients. Patients who declined another series of repetitive endoscopies were asked to undergo elective endoscopy at conclusion of the study. Patients on aspirin, NSAID, or maintenance H2RA therapy were excluded.

Materials and Methods

Source Population

Consecutive dyspeptic patients referred for diagnostic upper gastrointestinal endoscopy with endoscopically proven active peptic ulcers (either duodenal ulcer or gastric ulcer) and proven H. pylori infection were included in the study. All were enrolled between 1984 and 1994 and also participated in sequential H. pylori eradication trials. Patients willing to

Abbreviations used in this paper: CBS, colloidal bismuth subcitrate; H2RA, histamine2-receptor antagonist.
ulcer relapse and H. pylori eradication

October 1997

the years, consisting of either bismuth monotherapy (colloidal bismuth subcitrate [CBS]); bismuth dual therapy (CBS-metronidazole/CBS-amoxicillin); bismuth triple therapy (CBS-amoxicillin-metronidazole/CBS-tetracycline-metronidazole); or proton pump inhibitor dual therapy (omeprazole-amoxicillin/omeprazole-clarithromycin). The administration of a certain therapy depended on the advised therapy regimen at that time. Patients underwent sequential H. pylori eradication attempts until the infection was cured.

**Study Population**

Follow-up scheme. After complete healing of the ulcer, discontinuation of acid-suppressive therapy (only on-demand use was allowed), and successful H. pylori eradication, all patients were followed up by endoscopy at 3-month intervals for the first year. All patients were instructed to contact the responsible physician if dyspeptic symptoms recurred, and these patients were permitted to resume taking H2RA until endoscopy was performed (within 2 days).

After the first year, elective follow-up endoscopies were performed half-yearly in those patients willing to undergo these sequential examinations. The remaining patients were contacted again in 1995 to assess symptom recurrence and were asked to undergo one elective follow-up endoscopy. The follow-up period lasted until the end of the study in 1995.

**Definition of Ulcer Recurrence**

Peptic ulcer relapse was defined as endoscopically confirmed recurrent peptic ulcer after endoscopically proven healing of the initial ulcer. By definition, superficial erosions were not considered to be ulcers.

**Results**

Two hundred forty-seven patients (183 patients with duodenal ulcers and 64 patients with gastric ulcers) were enrolled. H. pylori infection was cured in 186 of 247 patients (75%). These 186 H. pylori−negative patients underwent endoscopy every 3 months in the first year

---

**H. pylori Assessment**

*H. pylori* assessment was performed before and 4–6 weeks after completion of each *H. pylori* eradication attempt and at all endoscopies performed during follow-up. Four gastric antrum biopsy specimens were routinely taken for culture (n = 2) and histopathology (n = 2). Corpus biopsy specimens for culture (n = 2) and histopathology (n = 2) were taken when proton pump inhibitors became part of therapy.

Formalin-fixed gastric biopsy specimens were stained with H&E for histopathologic examination, and two histopathologists examined the preparations independently. If the stain revealed no microorganisms, no additional special staining was performed. Culture of gastric biopsy specimens was performed on selective blood agar plates (no. 2 Columbia agar; Oxoid Ltd., London, England, supplemented with horse blood, 5% by volume, and Skirrow supplement; Oxoid), under microaerophilic conditions. Gram-negative and oxidase-, catalase-, and urease-positive spiral, curved rods were identified as *H. pylori*.32 The microbiologist and histopathologists performing the tests were unaware of each others' results. *H. pylori* infection was present if results of culture and/or histopathological assessment were positive. Cure of *H. pylori* infection was defined as absence of *H. pylori* in both culture and histopathological examination.

**Administered Therapies**

Once an active ulcer was diagnosed, acid-suppressive therapy was administered until the ulcer was completely healed as confirmed by endoscopy. After complete ulcer healing, acid-suppressive therapy was discontinued, and H2RA was used only on demand.

After documented ulcer healing, an *H. pylori* eradication regimen was started. Eradication therapies have varied over years, consisting of either bismuth monotherapy (colloidal bismuth subcitrate [CBS]); bismuth dual therapy (CBS-metronidazole/CBS-amoxicillin); bismuth triple therapy (CBS-amoxicillin-metronidazole/CBS-tetracycline-metronidazole); or proton pump inhibitor dual therapy (omeprazole-amoxicillin/omeprazole-clarithromycin). The administration of a certain therapy depended on the advised therapy regimen at that time. Patients underwent sequential H. pylori eradication attempts until the infection was cured.
Table 1. Demography and Clinical Outcome of Patients With Duodenal and Gastric Ulcer Disease

<table>
<thead>
<tr>
<th></th>
<th>Duodenal ulcer disease</th>
<th>Gastric ulcer disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Included patients (n)</td>
<td>183</td>
<td>64</td>
</tr>
<tr>
<td>Mean age, yr (range)</td>
<td>48.2 (23.2–85.9)</td>
<td>54.0 (29.5–78.2)</td>
</tr>
<tr>
<td>Sex: M/F (%/%)</td>
<td>118/65 (64.5/35.5)</td>
<td>42/22 (65.5/34.4)</td>
</tr>
<tr>
<td>Successful H. pylori eradication</td>
<td>141</td>
<td>45</td>
</tr>
<tr>
<td>Follow-up after H. pylori eradication, yr (range)</td>
<td>2.6 (0.6–9.2)</td>
<td>2.5 (0.5–9.8)</td>
</tr>
<tr>
<td>Patient-years after H. pylori eradication</td>
<td>367</td>
<td>113</td>
</tr>
<tr>
<td>Ulcer relapse rate (n)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

NOTE. Demography and clinical outcome of patients with endoscopically proven duodenal or gastric ulcer disease. Patients in whom H. pylori was successfully eradicated were subjected to long-term follow-up for up to 9.8 years. Patients who underwent maintenance treatment with H 2RA or NSAIDs or patients with carcinoma were excluded.

after documented ulcer healing. Demographic characteristics and clinical outcome are summarized in Table 1.

After the first year of follow-up, 96 patients (64 with duodenal ulcers and 32 with gastric ulcers) remained available for scheduled half-yearly endoscopies. The remaining 89 patients (74 with duodenal ulcers and 15 with gastric ulcers) who declined repetitive elective follow-up endoscopy were monitored for recurring symptoms and received requests for follow-up endoscopy in 1995. Sixty-one of them underwent follow-up endoscopy in 1995, whereas 28 (24 with duodenal ulcers and 4 with gastric ulcers) refused to do so. These 28 patients had documented cure of the infection at the end of the first year of follow-up after successful H. pylori eradication and had no recurrent symptoms through the end of follow-up.

**Outcomes of patients with duodenal ulcers.** H. pylori eradication was successful in 141 of 183 patients with duodenal ulcer disease. None had a duodenal ulcer relapse. The median follow-up period after successful H. pylori eradication in these patients was 2.6 years, ranging from 0.6 to 9.2 years, corresponding to 367 patient-years.

**Outcomes of patients with gastric ulcers.** H. pylori eradication was successful in 45 of 64 patients with gastric ulcer disease. None had a recurrent gastric ulcer. The median H. pylori—negative follow-up period in these patients was 2.5 years, ranging from 0.5 to 9.8 years, corresponding to 113 patient-years.

**Discussion**

This is the first prospective long-term study showing complete absence of relapse of duodenal or gastric ulcers after successful eradication of H. pylori for a maximum of 9.8 years in patients not using aspirin or NSAIDs.

H. pylori infection is associated with recurrence of duodenal and gastric ulcers as confirmed by a large body of literature that also stresses that ulcer recurrence is less frequent after its eradication after, on average, 1 year of follow-up. Combined data from 30 pilot and controlled studies show an overall duodenal ulcer relapse rate of 61% (range, 20%–100%) in patients who remain H. pylori positive compared with 3% (range, 0%–22%) in patients free of H. pylori. A few studies have reported gastric ulcer relapse rate in relation to H. pylori status, with a mean follow-up period of 9 months (range, 3–12 months). Gastric ulcers relapsed on average in 52% of patients who remained H. pylori positive compared with 2% of the cured patients. Only two studies have followed up on patients after healing of duodenal or gastric ulcer for a prolonged period. Forbes et al. reported on follow-up for 7 years (mean, 6.5 years; range, 5.1–7.6 years), but 37% of their patients were lost before final follow-up endoscopy. The duodenal ulcer relapse rate in H. pylori—positive patients was 20% compared with 3% in H. pylori—negative patients. Interpretation of the relapse rates, however, is hampered by the fact that H. pylori was assessed by “clearance” and not “eradication” of H. pylori.

For 4 years Labenz et al. followed up on 190 patients with duodenal ulcers after H. pylori eradication by annual endoscopy, or when patients were symptomatic, and found a mean annual duodenal ulcer relapse rate of 0.9% per patient-year and concomitant reinfection after successful eradication of H. pylori. Because no DNA fingerprinting of the isolated H. pylori strains was performed, it remains speculative whether these recurrent infections were due to a new H. pylori infection or recrudescence. The incidence of apparent new infections, however, is higher compared with the natural acquisition rate of the infection, which is reported to be approximately 0.3% in the Western world. This indicates the possibility of recrudescence rather than reinfection. Moreover, Bell and Powell’s study indicates that the majority of H. pylori reinfections occur in the first 12 months of follow-up after apparent H. pylori eradication, a period in which recrudescence is to be expected. In our study, duodenal as well as gastric ulcer relapses did not occur in the H. pylori—eradicated patients even after follow-up for up to 9.8 years. We did not observe reinfection in any of these patients. The absence of recurrence of H. pylori infection after apparent successful eradication is in agreement with the results of our reinfection study, which includes a substantial number of nonulcer patients. Reoccurrence of H. pylori infection was proved in 9 of 173 cured pa-
patients. Two patients had an iatrogenically transmitted reinfection with \(H. pylori\), as classified by DNA analysis of pre-eradication and post-eradication strains. Recurrence of \(H. pylori\) infection was likely in 6 of 7 patients (identical DNA pattern pre-eradication and post-eradication). Reoccurrence of \(H. pylori\) infection in 1 patient could not be classified because the pre-eradication strain was lost.

All the patients with reoccurrence of \(H. pylori\) infection had functional dyspepsia at study entry, and no ulcer was noticed by repeated endoscopies during follow-up. It is obvious that persistent or recrudescent \(H. pylori\) infection, despite attempted \(H. pylori\) eradication, is accompanied by recurrence of initially healed ulcers (data not shown). Studies of relapse rates of duodenal or gastric ulcers are complicated by several additional possible confounders. The loss of patients and the sometimes retrospective character may lead to patient selection bias. Because \(H. pylori\) infection is associated with ulcer disease, the ulcer relapses will also be related to recurrent infection. It is therefore crucial that \(H. pylori\) eradication is documented accurately. Most of the studies report ulcer relapse rates (1%–22%) despite the apparent absence of \(H. pylori\) infection after eradication therapy. However, in several of these studies, it is obvious that “clearance” of \(H. pylori\) infection rather than “eradication” was used to assess cure of the infection. These studies report, as expected, higher ulcer relapse rates during presumed \(H. pylori\) negative follow-up, ranging from 3% to 22%.

Our study outcome contrasts with those of the aforementioned studies, with the difference probably caused by the assessment of cure of \(H. pylori\) infection undertaken at least 4 weeks after the cessation of \(H. pylori\) eradication therapy using different methods (culture and histology). These procedures may have avoided false-negative \(H. pylori\) assessments. \(H. pylori\) eradication therapy may have been less effective in the early studies. Using these less effective \(H. pylori\) eradication regimens, apparent reinfection may occur even after 1 year of follow-up, which, as expected, is associated with ulcer recurrence. Because in most studies of duodenal ulcer, relapse patients were followed up for up to 12 months, some of the ulcer relapses may be explained by late recurrence of \(H. pylori\) infection. In our study, less effective therapies were used in the early phase; however, because the follow-up period was for more than 1 year, and because of detailed assessment of the eradication of \(H. pylori\) infection, it was finally possible to show that no \(H. pylori\) reinfection had taken place, and, therefore, in cases of documented, successful \(H. pylori\) eradication, no recurrence of ulcers occurred.

Interpretation of ulcer-relapse data is even more difficult for studies reporting on ulcer recurrence without relating to the current \(H. pylori\) status. Furthermore, patients should only be included in ulcer-relapse follow-up studies after endoscopic proof of healing of the initial ulcer. Patients with inactive ulcer or functional dyspepsia should be excluded.

Nevertheless, studies performed with appropriate diagnostic accuracy still report \(H. pylori\)-negative ulcer relapses. In these cases, the (occult) use of aspirin or NSAIDs may account for recurrent ulcers in the absence of \(H. pylori\) infection. A recent review reported that NSAID use has been excluded in only one study. The exclusion of patients using NSAIDs or aspirin is probably the other important reason for the complete absence of ulcer relapses in our study.

Published studies on gastric ulcer relapse are scarce, and the follow-up periods do not exceed 12 months. In our study, patients with gastric ulcers were followed for up to 9.8 years after \(H. pylori\) eradication. The difference in outcome on ulcer relapse rates between our study and other published studies is probably mainly related to the fact that we vigorously excluded patients on NSAID or aspirin therapy. If, after exclusion of these confounders, \(H. pylori\)-negative duodenal or gastric ulcers remain, other rare causes, such as Crohn’s disease and Zollinger–Ellison syndrome, should be excluded.

In conclusion, relapses of duodenal or gastric ulcers remain absent after true eradication of \(H. pylori\), even after follow-up of up to 9.8 years. Eradication of \(H. pylori\) should therefore become mandatory treatment for both duodenal and gastric ulcer disease. Ulcer disease that has been lifelong and recurrent, possibly accompanied by potentially life-threatening complications, can be cured definitively once its causative agent, \(H. pylori\), has been eradicated.

References

6. Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effects of


